Genmab A/S Touts Strong 2025, Teases Catalyst-Heavy 2026 With Potential 2027 Launches [Yahoo! Finance]
Genmab A/S - American Depositary Shares (GMAB)
Company Research
Source: Yahoo! Finance
set up multiple launches in 2027, according to remarks made by Chief Financial Officer Anthony Pagano and Chief Commercial Officer Brad Bailey at a Leerink Partners event hosted by analyst Jonathan Chang. Pagano said 2025 featured strong revenue growth, disciplined operating expense management, and increased conviction across Genmab's late-stage pipeline, which he described as centered on three programs: EPKINLY Rina-S , and petosemtamab . Management said each program generated meaningful clinical data in 2025 and is expected to deliver registrational readouts in 2026, with potential launches in 2027. Late-stage pipeline: peak sales targets and expansion strategy ? Data Storage to Data Intelligence: Everpure's Big AI Era Rebrand Bailey said Genmab continues to view EPKINLY as a blockbuster with $3 billion-plus potential, with the core commercial strategy focused on moving the CD20 bispecific into earlier lines of therapy. He added that the company has been encouraged by uptake
Show less
Read more
Impact Snapshot
Event Time:
GMAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GMAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GMAB alerts
High impacting Genmab A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
GMAB
News
- Genmab And Lundbeck Amlenetug Data Adds Nuance To Valuation Debate [Yahoo! Finance]Yahoo! Finance
- Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees in Genmab [Yahoo! Finance]Yahoo! Finance
- Genmab A/S (GMAB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- Genmab A/S (GMAB) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $40.00 price target on the stock.MarketBeat
- Transactions in Connection with Share Buy-back Program [Yahoo! Finance]Yahoo! Finance